Regional, Synaptic, Cellular Modulation of Abeta Metabolism
Regional, Synaptic, Cellular Modulation of Abeta Metabolism
批准号:
9764499
负责人:
DAVID M. HOLTZMAN
金额:
$146.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-15 至 2022-08-31
关键词:
Abeta clearanceAbeta synthesisAddressAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloid beta-ProteinAmyloid beta-Protein PrecursorAmyloidosisAnimalsApolipoprotein EBiochemicalBiological ProcessBrainCell Surface ReceptorsCellsCellular biologyClinicalComplementCoupledDNA Sequence AlterationDataDementiaDiseaseDisease ProgressionEventExperimental DesignsExtracellular SpaceFundingGenesGeneticGrantHeparan Sulfate ProteoglycanHumanImpaired cognitionIn VitroInflammationLaboratoriesLate Onset Alzheimer DiseaseLeadLinkMAPT geneMetabolismMicrodialysisMissionMonitorMusNational Institute of Neurological Disorders and StrokeNerve DegenerationNervous system structureNeurodegenerative DisordersNeurodevelopmental DisorderNeuronsPathogenesisPathologicPathway interactionsPlayProbabilityProductionProteinsPublic HealthRegulationRoleSigns and SymptomsSleepSleep Wake CycleSynapsesSynaptic TransmissionTauopathiesTechniquesTimeViral VectorWorkabeta accumulationabeta depositionawakecell typedesigner receptors exclusively activated by designer drugsgenetic risk factorin vivoinnovationinsightmouse modelnoveloptogeneticspresenilin-1presenilin-2protein aggregateprotein aggregationreceptorsynucleintau Proteinstau aggregationtau conformation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Alzheimer's disease (AD) is the most common cause of dementia and a major public health problem. Data
from genetic, biochemical, animal, and human studies suggest that the amyloid-β (Aβ) peptide plays a key
early role in initiating disease pathogenesis and that the microtubule associated protein tau plays a critical role
in neurodegeneration and disease progression. Progressive accumulation of Aβ in the brain appears to
ultimately lead to and exacerbate downstream events directly linked to cognitive decline and dementia such as
inflammation and tau aggregation. Prior to this PPG proposal, we found that synaptic and network activity is
tightly coupled with the release of the Aβ peptide in the extracellular space of the brain as part of a normal
biological process. Our labs discovered some of the cellular mechanisms that link synaptic transmission and
network activity with dynamic changes in Aβ levels in awake, behaving mice with confirmation in human
studies. This collaborative work led to the submission and funding of the current PPG which has been funded
from 4/1/12 to the present. We have made substantial progress over the last 4 years. Some key findings are
that the sleep/wake cycle regulates Aβ levels dynamically with Aβ release being higher during wake and lower
during sleep. This effect, at least in part, is via neuronal activity differences between wake and sleep. We also
found that Aβ and tau release by neurons is controlled by synaptic activity and can be monitored dynamically.
It was also found that Aβ levels, clearance, and aggregation can be strongly influenced by neuronal LRP1 and
heparan sulfate proteoglycans (HSPG). In addition to our findings, increasing evidence indicates that once key
proteins involved in neurodegenerative diseases aggregate in the brain (e.g. Aβ and tau), they appear to
spread from one region to others within neuronal networks that are synaptically connected. There is also
growing evidence that in AD, Aβ aggregation in some way drives the progression and spread of tauopathy. We
believe that new studies are now warranted to understand the relationship between synaptic and network
activity, the sleep/wake cycle, and the impact of the apoE/HSPG/LRP1 on Aβ, tau, and the spreading of these
protein aggregates in the brain. The overall hypothesis of this PPG renewal is that the sleep-wake cycle and
brain network activity modulates both Aβ and tau aggregation and the effect of Aβ on tau spreading. We further
hypothesize that apoE/LRP1/HSPG pathways influence these effects. We will utilize innovative techniques and
approaches to study these hypotheses such as the use of DREADDs, in vivo microdialysis, and
microimmunoelectrodes as well as a variety of genetically modified mouse models and viral vectors. The
specific projects and Cores are listed here. Project 1, D. Holtzman, PI: Effects of the sleep/wake cycle on Aβ,
tau, and spreading. Project 2, J. Cirrito, PI: Neuronal Network Regulation in Aβ and Tau Conformation and
Spreading. Project 3, G. Bu, PI: Neuronal LRP1 and HSPG in pathological spreading of Aβ and tau. Core A:
Administration (D. Holtzman, PI); Core B: Viral Vectors Core (B. J. Snider, PI).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
-
批准号:10674679
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2022
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10667466
-
项目类别:
-
资助金额:$53.02万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10407944
-
项目类别:
-
资助金额:$54.01万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administration Core
-
批准号:10622634
-
项目类别:
-
资助金额:$80.27万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Alzheimer's Disease Research Center
-
批准号:10622633
-
项目类别:
-
资助金额:$307.63万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau
-
批准号:9815588
-
项目类别:
-
资助金额:$369.43万
-
财政年份:2019
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Nervous System Development and Injury
-
批准号:9386458
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2016
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:8779836
-
项目类别:
-
资助金额:$59.46万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9060227
-
项目类别:
-
资助金额:$55.3万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9814735
-
项目类别:
-
资助金额:$376.01万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10006905
-
项目类别:
-
资助金额:$7.01万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8642679
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Dynamic Regulation of Amyloid-^ in the CNS
-
批准号:8331629
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8838268
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Effects of the Sleep/Wake Cycle on A-Beta, Tau and Spreading
-
批准号:10006907
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10246278
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10246274
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10006909
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8467068
-
项目类别:
-
资助金额:$110.69万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8268731
-
项目类别:
-
资助金额:$116.73万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位: